Use of Selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot

Epidemiology

Volumn 25, Issue 6, 2014, Pages 859-865

  Yazdy, Mahsa M ^a   Mitchell, Allen A ^a   Louik, Carol ^a   Werler, Martha M ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ANTIDEPRESSANT AGENT;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CLUBFOOT; CONTROLLED STUDY; DEPRESSION; DRUG USE; FAMILY HISTORY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SMOKING; NEWBORN; PARITY; POPULATION BASED CASE CONTROL STUDY; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SMOKING; UNITED STATES; ABNORMALITIES, DRUG-INDUCED; ANXIETY; CASE CONTROL STUDY; CHEMICALLY INDUCED; INTERVIEW; PREGNANCY COMPLICATIONS; RISK;

ABNORMALITIES, DRUG-INDUCED; ANTIDEPRESSIVE AGENTS; ANXIETY; CASE-CONTROL STUDIES; CLUBFOOT; DEPRESSION; FEMALE; HUMANS; INFANT, NEWBORN; INTERVIEWS AS TOPIC; MASSACHUSETTS; NEW YORK; NORTH CAROLINA; PREGNANCY; PREGNANCY COMPLICATIONS; RISK; SEROTONIN UPTAKE INHIBITORS;

EID: 84927743101     PISSN: 10443983     EISSN: 15315487     Source Type: Journal    
DOI: 10.1097/EDE.0000000000000157     Document Type: Article

References (26)

1. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM; National Birth Defects Prevention Study. Patterns of antidepressant medication use among pregnant women in a United States population. J Clin Pharmacol. 2011;51:264-270.
2. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196:544.el-544.e5.
3. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH Jr, Watson WJ. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. J Clin Psychopharmacol. 2008;28:714-716.
4. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell A A. Firsttrimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007;356:2675-2683.
5. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. 2009;339:b3569.
6. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jongvan den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol. 2010;88:94-100.
7. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol. 2011;91:142-152.
8. Malm H, Artama M, Gissler M, Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111-120.
9. Moore KL, Persaud TVN, Torchia MG, Persaud T. The Developing Human: Clinically Oriented Embryology. Philadelphia, Pa: Saunders/Elsevier; 2008.
10. Sadler TW. Longmans medical embryology. Philadelphia, PA: Wolters Kluwer Health; 2011.
11. Anand A, Sala DA. Clubfoot: etiology and treatment. Indian J Orthop. 2008;42:22-28.
12. Porter RW. Congenital talipes equinovarus: I. Resolving and resistant deformities. J Bone Joint Surg Br. 1987;69:822-825.
13. Parker SE, Mai CT, Strickland MJ, et al.; National Birth Defects Prevention Network. Multistate study of the epidemiology of clubfoot. Birth Defects Res A Clin Mol Teratol. 2009;85:897-904.
14. Wynne-Davies R. Family studies and aetiology of club foot. J Med Genet. 1965;2:227-232.
15. Werler MM, Yazdy MM, Mitchell A A, et al. Descriptive epidemiology of idiopathic clubfoot. Am J Med Genet A. 2013;161A:1569-1578.
16. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM; National Birth Defects Prevention Study. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 2007;356:2684-2692.
17. Altura BM, Malaviya D, Reich CF, Orkin LR. Effects of vasoactive agents on isolated human umbilical arteries and veins. Am J Physiol. 1972;222:345-355.
18. Bjoro K, Stray-Pedersen S. In vitro perfusion studies on human umbilical arteries. I. Vasoactive effects of serotonin, PGF2 alpha and PGE2. Acta Obstet Gynecol Scand. 1986;65:351-355.
19. González C, Cruz MA, Gallardo Y Albornoz J, Bravo I. Serotonininduced vasoconstriction in human placental chorionic veins: interaction with prostaglandin F2 alpha. Gynecol Obstet Invest. 1993;35:86-90.
20. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: a review. JVet Pharmacol Ther. 2008;31:187-199.
21. Clark KE, Mills EG, Otte TE, Stys SJ. Effect of serotonin on uterine blood flow in pregnant and nonpregnant sheep. Life Sci. 1980;27:2655-2661.
22. Lang U, Prada J, Clark KE. Systemic and uterine vascular response to serotonin in third trimester pregnant ewes. Eur J Obstet Gynecol Reprod Biol. 1993;51:131-138.
23. Philip J, Silver RK, Wilson RD, et al.; NICHD EATA Trial Group. Late first-trimester invasive prenatal diagnosis: results of an international randomized trial. Obstet Gynecol. 2004;103:1164-1173.
24. Stoler JM, McGuirk CK, Lieberman E, Ryan L, Holmes LB. Malformations reported in chorionic villus sampling exposed children: a review and analytic synthesis of the literature. Genet Med. 1999;1:315-322.
25. Van Allen MI. Structural anomalies resulting from vascular disruption. Pediatr Clin North Am. 1992;39:255-277.
26. Miller K, Massie MJ. Depression and anxiety. Cancer J. 2006;12:388-397.